Zoetis Inc
$
101.97
-0.96 (-0.93%)
| Volume: | 2,042,107 | Avg Vol (1m): | 1,929,177 |
| Market Cap $: | 48.81 Bil | Enterprise Value $: | 53.46 Bil |
| P/E (TTM): | 35.65 | P/B: | 21.26 |
| Earnings Power Value | 16.6 |
| Net Current Asset Value | -8.67 |
| Tangible Book | -4.54 |
| Projected FCF | 25.56 |
| Median P/S Value | 60.83 |
| Graham Number | 0 |
| Peter Lynch Value | 61.92 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.28 |
Cash-To-Debt ranked
lower than
78.58%
of
859
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
ZTS:
0.28
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.09, Med: 0.16, Max: 4.34
Current: 0.28
|
| Equity-to-Asset | 0.21 |
Equity-to-Asset ranked
lower than
90.86%
of
788
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
ZTS:
0.21
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.12, Med: 0.2, Max: 0.69
Current: 0.21
|
| Debt-to-Equity | 2.78 |
Debt-to-Equity ranked
lower than
96.31%
of
596
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
ZTS:
2.78
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.02, Med: 2.85, Max: 5.14
Current: 2.78
|
| Debt-to-EBITDA | 2.91 |
Debt-to-EBITDA ranked
lower than
57.98%
of
495
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
ZTS:
2.91
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 0.08, Med: 2.73, Max: 5.61
Current: 2.91
|
| Interest Coverage | 8.60 |
Interest Coverage ranked
lower than
70.06%
of
648
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
ZTS:
8.6
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 7.26, Med: 8.53, Max: 26.77
Current: 8.6
|
| Piotroski F-Score | 5 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 5.34 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.52 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 24.41%
WACC 5.83%
| ||
Profitability & Growth : 7/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 31.25 |
Operating Margin ranked
higher than
95.13%
of
801
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
ZTS:
31.25
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 7.79, Med: 19.7, Max: 32.5
Current: 31.25
|
| Net Margin % | 23.47 |
Net Margin ranked
higher than
87.03%
of
802
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
ZTS:
23.47
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -3.62, Med: 10.56, Max: 24.52
Current: 23.47
|
| ROE % | 65.78 |
ROE ranked
higher than
98.08%
of
832
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
ZTS:
65.78
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: 6.58, Med: 28.5, Max: 72.21
Current: 65.78
|
| ROA % | 14.05 |
ROA ranked
higher than
86.57%
of
871
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
ZTS:
14.05
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 4.16, Med: 7.86, Max: 14.75
Current: 14.05
|
| ROC (Joel Greenblatt) % | 59.08 |
ROC (Joel Greenblatt) ranked
higher than
90.88%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
ZTS:
59.08
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 16.99, Med: 29.85, Max: 61.8
Current: 59.08
|
| 3-Year Total Revenue Growth Rate | 6.90 |
3-Year Revenue Growth Rate ranked
lower than
55.01%
of
689
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 291.9, Med: 5.8, Min: -100
ZTS:
8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 2.5, Med: 4.1, Max: 16.3
Current: 8
|
| 3-Year Total EBITDA Growth Rate | 36.40 |
3-Year EBITDA Growth Rate ranked
higher than
72.87%
of
704
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
ZTS:
37.8
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -2.8, Med: 21.4, Max: 677.8
Current: 37.8
|
| 3-Year EPS w/o NRI Growth Rate | 62.70 |
3-Year EPS w/o NRI Growth Rate ranked
higher than
61.09%
of
663
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
ZTS:
62.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 14.7, Max: 62.7
Current: 62.7
|
» ZTS's 30-Y Financials
Financials (Next Earnings Date: 2019-08-02)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:ZTS
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Specialty & Generic   NAICS : 325412   SIC : 2834 |
| Compare | NYSE:AGN XTER:MRK SHSE:600276 TSE:4502 TSE:4507 TSX:WEED XTAE:TEVA TSE:4523 NSE:SUNPHARMA NAS:MYL SZSE:000538 NYSE:ELAN SZSE:300122 SHSE:600196 SHSE:600332 XPAR:IPN TSX:ACB HKSE:03320 TSE:4506 XSWX:VIFN |
| Traded in other countries | ZOE.Germany 0M3Q.UK |
| Address | 10 Sylvan Way, Parsippany, NJ, USA, 07054 |
| Zoetis Inc sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns the majority of its revenue from production animals (cattle, pigs, poultry, and so on) but also sells companion animal (dogs, horses, cats) products. The firm has the largest market share in the industry and was previously Pfizer's animal health unit. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 35.65 |
PE Ratio ranked
lower than
73.97%
of
557
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
ZTS:
35.65
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 27.31, Med: 37.91, Max: 133.08
Current: 35.65
|
| Forward PE Ratio | 29.67 |
Forward P/E ranked
lower than
76.58%
of
111
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
ZTS:
29.67
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 35.65 |
PE without NRI ranked
lower than
73.38%
of
556
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
ZTS:
35.65
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 27.31, Med: 37.91, Max: 133.08
Current: 35.65
|
| Price-to-Owner-Earnings | 31.96 |
Price-to-Owner-Earnings ranked
lower than
50.31%
of
324
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
ZTS:
31.96
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 25.56, Med: 56.43, Max: 271.57
Current: 31.96
|
| PB Ratio | 21.26 |
PB Ratio ranked
lower than
97.56%
of
819
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
ZTS:
21.26
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 12.62, Med: 18.47, Max: 24.4
Current: 21.26
|
| PS Ratio | 8.37 |
PS Ratio ranked
lower than
78.32%
of
775
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
ZTS:
8.37
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 3.11, Med: 4.99, Max: 8.51
Current: 8.37
|
| Price-to-Free-Cash-Flow | 34.29 |
Price-to-Free-Cash-Flow ranked
lower than
50.67%
of
298
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
ZTS:
34.29
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 25.69, Med: 45.5, Max: 90.56
Current: 34.29
|
| Price-to-Operating-Cash-Flow | 27.63 |
Price-to-Operating-Cash-Flow ranked
lower than
60.20%
of
392
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
ZTS:
27.63
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 21.62, Med: 31.23, Max: 41.95
Current: 27.63
|
| EV-to-EBIT | 28.60 |
EV-to-EBIT ranked
lower than
68.36%
of
572
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
ZTS:
28.6
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 20.2, Med: 25.1, Max: 41.6
Current: 28.6
|
| EV-to-EBITDA | 24.14 |
EV-to-EBITDA ranked
lower than
70.52%
of
597
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
ZTS:
24.14
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 16.5, Med: 21, Max: 32.1
Current: 24.14
|
| EV-to-Revenue | 9.04 |
EV-to-Revenue ranked
lower than
76.23%
of
795
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
ZTS:
9.04
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 3.8, Med: 5.7, Max: 9.3
Current: 9.04
|
| PEG Ratio | 1.80 |
PEG Ratio ranked
lower than
61.51%
of
317
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
ZTS:
1.8
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 1.35, Med: 2.66, Max: 3.29
Current: 1.8
|
| Current Ratio | 4.05 |
Current Ratio ranked
higher than
72.98%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
ZTS:
4.05
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.96, Med: 2.86, Max: 4.38
Current: 4.05
|
| Quick Ratio | 2.79 |
Quick Ratio ranked
higher than
66.08%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
ZTS:
2.79
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.07, Med: 1.69, Max: 2.92
Current: 2.79
|
| Days Inventory | 259.81 |
Days Inventory ranked
lower than
91.26%
of
755
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
ZTS:
259.81
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 125.75, Med: 281.16, Max: 325.24
Current: 259.81
|
| Days Sales Outstanding | 59.87 |
Days Sales Outstanding ranked
higher than
66.36%
of
770
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
ZTS:
59.87
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 59.87, Med: 74.75, Max: 91.07
Current: 59.87
|
| Days Payable | 43.28 |
Days Payable ranked
lower than
73.61%
of
758
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
ZTS:
43.28
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 43.28, Med: 59.78, Max: 110.66
Current: 43.28
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 0.57 |
Trailing Dividend Yield ranked
lower than
85.77%
of
752
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
ZTS:
0.57
Ranked among companies with meaningful Trailing Dividend Yield only.
|
Trailing Dividend Yield range over the past 10 years
Min: 0.21, Med: 0.65, Max: 1.08
Current: 0.57
|
| Dividend Payout Ratio | 0.19 |
Dividend Payout Ratio ranked
higher than
78.20%
of
477
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 68, Med: 0.3, Min: 0.02
ZTS:
0.19
Ranked among companies with meaningful Dividend Payout Ratio only.
|
Dividend Payout Ratio range over the past 10 years
Min: 0.17, Med: 0.24, Max: 0.49
Current: 0.19
|
| 3-Year Dividend Growth Rate (Per Share) | 14.90 |
3-Year Dividend Growth Rate ranked
higher than
65.55%
of
299
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 114, Med: 7.4, Min: -100
ZTS:
14.9
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
|
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 24.9
Current: 14.9
|
| Forward Dividend Yield % | 0.64 |
Forward Dividend Yield ranked
lower than
85.67%
of
719
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
ZTS:
0.64
Ranked among companies with meaningful Forward Dividend Yield only.
| N/A |
| Yield-on-Cost (5-Year) % | 1.35 |
Yield-on-Cost (5y) ranked
lower than
85.91%
of
745
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
ZTS:
1.35
Ranked among companies with meaningful Yield-on-Cost (5y) only.
|
Yield-on-Cost (5y) range over the past 10 years
Min: 0.5, Med: 1.54, Max: 2.56
Current: 1.35
|
| 3-Year Share Buyback Rate | 1.20 |
3-Year Share Buyback Rate ranked
higher than
93.17%
of
571
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 100, Med: -5.3, Min: -815
ZTS:
1.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -0.1, Med: 0.2, Max: 1.2
Current: 1.2
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 3.99 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
79.68%
of
374
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 209, Med: 2.11, Min: 0.05
ZTS:
3.99
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.51, Med: 4.41, Max: 5.27
Current: 3.99
|
| Price-to-Median-PS-Value | 1.67 |
Price-to-Median-PS-Value ranked
lower than
82.23%
of
743
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
ZTS:
1.67
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.64, Med: 1.01, Max: 1.67
Current: 1.67
|
| Price-to-Peter-Lynch-Fair-Value | 1.65 |
Price-to-Peter-Lynch-Fair-Value ranked
lower than
71.23%
of
212
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
ZTS:
1.65
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
|
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 1.42, Med: 2.62, Max: 3.18
Current: 1.65
|
| Earnings Yield (Joel Greenblatt) % | 3.50 |
Earnings Yield (Greenblatt) ranked
higher than
54.79%
of
867
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
ZTS:
3.5
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.4, Med: 4, Max: 5
Current: 3.5
|
| Forward Rate of Return (Yacktman) % | 21.62 |
Forward Rate of Return ranked
higher than
76.48%
of
421
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
ZTS:
21.62
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: 12.8, Med: 16.1, Max: 22
Current: 21.62
|
More Statistics
| Revenue (TTM) (Mil) $ | 5,914 |
| EPS (TTM) $ | 2.86 |
| Beta | 0.64 |
| Volatility % | 15.72 |
| 52-Week Range $ | 78.9 - 103.97 |
| Shares Outstanding (Mil) | 478.66 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 5 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |